

# Journal of Visualized Experiments

## Enrichment and detection of Clostridium perfringens toxinotypes in retail food samples --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59931R2
Full Title:	Enrichment and detection of Clostridium perfringens toxinotypes in retail food samples
Keywords:	Clostridium perfringens; epsilon toxin; Genotype; Toxinotype; Retail food samples; American
Corresponding Author:	Jennifer Linden Cornell University Joan and Sanford I Weill Medical College New York, New York UNITED STATES
Corresponding Author's Institution:	Cornell University Joan and Sanford I Weill Medical College
Corresponding Author E-Mail:	jel2049@med.cornell.edu
Order of Authors:	Jennifer Linden Zuha Anwar Samantha B Regan
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Brain and Mind Institute, Weill Cornell Medical College, 1300 York Ave, New York, NY, USA, 10065

**TITLE:**

Enrichment and Detection of *Clostridium perfringens* Toxinotypes in Retail Food Samples

**AUTHORS AND AFFILIATIONS:**

Zuha Anwar<sup>1,\*</sup>, Samantha B. Regan<sup>1,\*</sup>, Jennifer Linden<sup>1</sup>

<sup>1</sup>Brain and Mind Institute, Weill Cornell Medical College, 1300 York Ave, New York, NY, USA, 10065

\*Co-first authors

**Corresponding Author:**

Jennifer Linden (jel2049@med.cornell.edu)

**Email Addresses of Co-Authors:**

Zuha Anwar (zuhaanwar@yahoo.com)

Samantha B. Regan (sar3006@med.cornell.edu)

**KEYWORDS:**

*Clostridium perfringens*, epsilon toxin, genotype, toxinotype, retail food samples, American

**SUMMARY:**

The objective of this protocol is to detect different *Clostridium perfringens* toxinotypes in locally purchased foods, particularly epsilon toxin producing strain types B and D, without the use of anaerobic chambers.

**ABSTRACT:**

*Clostridium perfringens* (*C. perfringens*) is a prolific toxin producer and causes a wide range of diseases in various hosts. *C. perfringens* is categorized into five different toxinotypes, A through E, based on the carriage of four major toxin genes. The prevalence and distribution of these various toxinotypes is understudied, especially their pervasiveness in American retail food. Of particular interest to us are the type B and D strains, which produce epsilon toxin, an extremely lethal toxin suggested to be the environmental trigger of multiple sclerosis in humans. To evaluate the presence of different *C. perfringens* toxinotypes in various food samples, we developed an easy method to selectively culture these bacteria without the use of an anaerobic container system only involving three culturing steps. Food is purchased from local grocery stores and transported to the laboratory under ambient conditions. Samples are minced and inoculated into modified rapid perfringens media (RPM) and incubated overnight at 37 °C in a sealed, airtight conical tube. Overnight cultures are inoculated onto a bottom layer of solid Tryptose Sulfite Cycloserine (TSC) agar, and then overlaid with a top layer of molten TSC agar, creating a “sandwiched”, anaerobic environment. Agar plates are incubated overnight at 37 °C and then evaluated for appearance of black, sulfite-reducing colonies. *C. perfringens*-suspected colonies are removed from the TSC agar using sterile eye droppers, and inoculated into RPM and sub-cultured overnight at 37 °C in an airtight conical tube. DNA is extracted from the RPM subculture, and then analyzed for the presence of *C. perfringens* toxin genes via polymerase chain reaction

(PCR). Depending on the type of food sampled, typically 15–20% of samples test positive for *C. perfringens*.

## INTRODUCTION:

*Clostridium perfringens* (*C. perfringens*) is a Gram positive, anaerobic, spore-forming, rod shaped bacterium that is found ubiquitously in the environment. This species of bacteria carries genes that encode for over 17 toxins and, historically, has been characterized into five toxinotypes (A-E) based on the presence of four different toxin genes: alpha, beta, epsilon, and iota toxin (**Table 1**)<sup>1</sup>. Recently, it has been suggested that this typing-scheme needs to be expanded to include types F and G, which harbor the *C. perfringens* enterotoxin (CPE) and NetB toxin, respectively<sup>2</sup>. However, more research is needed before this scheming system is formally accepted. While the alpha toxin gene is strictly chromosomally located, the CPE gene can be found both on the chromosome and plasmids. In comparison, the remaining toxins' genes are found on various differently-sized plasmids. We are particularly interested in the prevalence of *C. perfringens* types B and D as these strains produce epsilon toxin, an extremely potent, pore-forming toxin, which has been suggested to play a role in triggering multiple sclerosis (MS) in humans<sup>3-7</sup>. How people become infected or colonized by these strains is unknown. One possible explanation is through consumption of contaminated food products. To help answer this question, we sought to determine the prevalence of different *C. perfringens* toxinotypes in American food samples.

The presence of *C. perfringens* toxinotypes in American food samples is understudied and often requires use of anaerobic container systems and numerous sub-culturing steps<sup>8-11</sup>. Although numerous sub-culturing steps are needed to obtain purified isolates, this method can lead to loss of plasmids over time<sup>12-14</sup>, possibly affecting the detection of plasmid-borne toxin genes including the epsilon toxin gene. We sought to develop an easy method, with fewer sub-culturing steps, to selectively culture *C. perfringens* without the use of anaerobic chambers, jars, or bags. Briefly, food samples are inoculated into Rapid Perfringens Media (RPM) overnight (ON), then “sandwiched” into TSC agar and incubated ON. Colonies suspected to be *C. perfringens* are then sub-cultured into RPM and incubated again ON. DNA is extracted and PCR performed to determine genotype (**Figure 1**). We chose to use RPM as it has been demonstrated to increase the recovery of *C. perfringens* strains from food samples compared to other more standard media<sup>15</sup>. In addition, RPM was successfully used to isolate an epsilon toxin producing type B strain from an MS patient<sup>4</sup>. We use a modified version of RPM instead of the original version to allow easy DNA extraction. While this method allows easy identification of toxin genes within samples, it is possible that an individual sample will contain more than one *C. perfringens* toxinotype. Because our method does not isolate purified strains using multiple rounds of purification, identification of multiple toxinotypes from one sample is not possible. However, standard purification techniques (typically streaking onto TSC plates or blood agar plates) can be applied at the end of our protocol to achieve purified cultures.

## PROTOCOL:

NOTE: *C. perfringens* is considered a biosafety hazard level 2 (BSL2) organism. Although not all food samples will contain *C. perfringens*, all cultured samples should be treated as such. All

proper precautions and personnel protective equipment (PPE) should be worn at all times. Decontaminate all material prior to disposal.

## **1. Prepare modified RPM<sup>4,15</sup>**

1.1. Combine 30 g/L fluid thioglycolate medium, 60 g/L gelatin, 5 g/L peptone, 5 g/L glucose, 5 g/L potassium phosphate dibasic, 3 g/L yeast extract, 1.5 g/L sodium chloride, 0.5 g/L ferrous sulfate in deionized water until evenly dispersed. We typically make 1 L batches.

1.2. Autoclave at 121 °C for 15 min.

1.3. Allow to cool to approximately 40 °C.

1.4. Once RPM is cool, add D-cycloserine to a final concentration of 440 mg/L.

NOTE: Stock concentrations of D-cycloserine dissolved in sterile water at 50 mg/mL may be stored at -20 °C for future use.

1.5. Aseptically transfer 10 mL of RPM to 15 mL conical tubes. RPM can be prepared in batches and stored at 4 °C for up to one month.

1.6. Warm RPM to 37 °C prior to use.

## **2. Sample collection and RPM incubation**

2.1. Transport food to the laboratory under ambient temperatures within 1 h. Food may be transported in original packaging or sterile containers. If not testing immediately, food may be stored at -20 °C until use. Make note of the type of food and the country of origin according to the packaging label, if available, as well as any other relevant information.

2.2. Remove approximately 1.0–2.0 g of food and transfer to sterile Petri dish or equivalent. Finely mince with a sterile razor blade or scalpel.

2.3. Inoculate into 10 mL of phosphate buffered saline (PBS) in a 15 mL conical tube. Mix well.

2.3.1. To select for vegetative cells, transfer 5 mL of the PBS-food mixture into a 15 mL conical tube containing 10 mL of RPM. Secure the lid tightly.

2.3.2. To select for spores, heat the remaining 5 mL of PBS-food mixture at 85 °C for 15 min and then transfer to a 15 mL conical tube containing 10 mL of RPM. Secure the lid tightly.

2.4. Vortex and invert the food-RPM cultures to ensure complete mixing.

2.5. Tightly seal the conical tubes and wrap lids with paraffin film or plastic wrap to ensure an anaerobic environment.

2.6. Incubate overnight (ON) at 37 °C.

2.7. The following morning note any turbidity or fermentation in RPM tubes.

### 3. TSC “sandwich” plating

3.1. Inoculate ON RPM cultures into TSC agar using a “sandwich” technique (**Figure 2**) described below.

3.2. Prepare TSC agar as per the manufacturer's instructions.

3.2.1. Prepare the base layer of the TSC plates by transferring 10 mL of molten TSC agar to sterile Petri dishes and allow to solidify. These may be prepared in advanced and stored at 4 °C. Ensure plates are warmed to room temperature prior to use.

3.2.2. For the top layer of the TSC plate, maintain the remaining molten TSC agar at 40 °C.

NOTE: Although agar’s melting point is above 85 °C, molten agar solidifies around 32–45 °C.

3.3. Carefully retrieve the ON RPM cultures and transfer 100 µL to the TSC agar base. Because of fermentation, some cultures may be under pressure. Be sure to wear all appropriate PPE.

3.4. Spread the RPM inoculum using sterilized glass beads or cell spreader.

3.5. Allow RPM to be “absorbed” into TSC agar for 5–10 min at room temperature.

3.6. Carefully transfer 20 mL of molten, 40 °C TSC agar to plate using a serological pipette.

3.7. Replace the Petri dish lid and allow TSC agar to completely solidify at room temperature.

3.8. Invert the Petri dish and incubate at 37 °C ON.

3.9. If serial dilutions are desired, perform dilutions of the ON RPM cultures into fresh, pre-warmed RPM prior to inoculation into TSC agar.

### 4. Sub-culturing of sulfite-reducing colonies

4.1. The following morning, remove plates from incubator and examine for bacterial growth. Aerobic bacteria may be present on the surface of the agar. Anaerobic bacteria will be found growing embedded within the agar. Sulfite-reducing bacteria will turn surrounding agar black. Possible *C. perfringens* colonies will be black and embedded in the agar.

4.2. *C. perfringens* suspected colonies will be positive for sulfite reduction and will appear black, embedded within the agar. Using a sterile, single-use eyedropper, “pluck” the black colonies from the agar and transfer to 10 mL of fresh RPM in a 15 mL conical tube. It is important that the air from the eyedropper be expelled prior to piercing agar.

4.3. If there is a dense amount of aerobic bacterial growth on the surface of the plate, use a sterile cell scraper to remove colonies from selected areas. Multiple *C. perfringens* suspected colonies can be sampled from the same TSC plate into separate RPM cultures.

4.4. Tightly secure conical tube lids and wrap in paraffin film or plastic wrap. Incubate ON at 37 °C.

## 5. DNA Extraction

5.1. Remove ON RPM cultures and examine for signs of growth including turbidity and fermentation.

5.2. Gently invert RPM culture to disperse any settled bacteria and carefully open. Transfer 1 mL of the culture to a microcentrifuge tube.

5.3. Centrifuge at top speed (approximately 15,000 x g) for 10 min to pellet bacteria.

5.4. Wash pellet with 1 mL of sterile PBS.

5.4.1. In some circumstances, undigested gelatin will settle on top of pelleted bacteria. To remove gelatin, “fluff” off gelatin by gently agitating with PBS using a micropipette. This will “fluff-up” the gelatin while leaving the bacterial pellet intact.

5.4.2. Remove the PBS-gelatin mixture with gentle aspiration. Re-suspend the remaining bacterial pellet with 1 mL of fresh PBS.

5.5. Centrifuge the resuspended bacterial pellet at top speed for 10 min and carefully aspirate the supernatant.

5.6. Immediately perform DNA extraction using a DNA extraction kit and a protocol specifically created for extraction DNA from Gram-positive bacteria (see the **Table of Materials**).

5.7. Use the extracted DNA immediately or store at -20 °C until PCR analysis.

## 6. Detection of *C. perfringens* via PCR genotyping

6.1. To determine if cultures are positive for *C. perfringens* toxinotypes, examine extracted DNA for different toxin genes via PCR.

NOTE: Because we are most interested in the epsilon toxin producing strains type B and D *C. perfringens*, we evaluate for the presence of the alpha, beta, and epsilon toxin genes. Primers are listed in **Table 2**. Primers for 16s ribosomal DNA are used as a DNA extraction control. Additional primers can be used to test for toxinotypes A through G and can be found in published literature<sup>2, 12-13</sup>.

6.2. Use previously extracted *C. perfringens* DNA as a positive control. This control ensures that all components of the PCR reactions are working. We use DNA extracted from *C. perfringens* type B (ATCC 3626) as our positive control. Grow ATCC 3636 ON in RPM at 37 °C and extract DNA using the same methods described in steps 5.1–5.7. Store extracted DNA at -20 °C until use.

6.3. Set PCR conditions as follows: 94.0 °C for 3 min; 94.0 °C for 30 s; 47.9 °C for 30 s, 72.0 °C for 1 min (Repeat steps 2–4 for 35 cycles); 72.0 °C for 10 min.

6.4. To confirm PCR products, run PCR reactions on a 1.8 g/100 mL agarose gel using standard techniques. Expected PCR product sizes are listed in **Table 2**. Typical PCR results are displayed in **Figure 3**.

#### REPRESENTATIVE RESULTS:

Using this method, 15–20% of our sampled foods test positive for *C. perfringens*. While most strains are positive for toxinotype A, we have successfully detected both Type B and D in food samples. In a previously published paper we tested a total of 216 food samples purchased from New York retail stores<sup>16</sup> (**Table 3**). These samples included various meat samples (beef, lamb, pork and lamb), poultry samples (chicken and turkey), and seafood samples (cod, salmon, shellfish, snapper, flounder, squid, tilapia, tuna, and various other fishes). Produce and dairy samples were also tested. Of 216 samples, 34 (16%) were positive for *C. perfringens*. Of the 34 *C. perfringens* positive samples, 31 samples (91.2%) contained the alpha toxin, one sample (2.9%) contained the alpha, beta and epsilon toxin, and two samples (5.9%) contained the alpha and epsilon toxin.

Interestingly, we also discovered that *C. perfringens* was more prevalent as vegetative cells compared to spores. Twenty-five samples were compared for the presence of vegetative *C. perfringens* cells or spores. Spores were selected for by heat shocking samples at 85 °C for 15 min. Of the 25 samples tested, 16% were positive for vegetative *C. perfringens* strains versus 4% for spores. This indicates that it may be more cost effective to test for only vegetative cells instead of both.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: Overview of procedure.** Food samples are minced and diluted into sterile PBS. Half of the PBS-food sample is inoculated into RPM to select for vegetative cells. The remaining PBS-food sample is heat shocked at 85 °C for 15 min to select for spores prior to inoculation in RPM. Cultures are incubated ON at 37 °C then plated into TSC agar. TSC agar is incubated ON at 37 °C

and black, sulfite-reducing cultures are sub-cultured into fresh RPM. Sub-cultured RPM cultures are incubated ON at 37 °C and DNA is extracted to perform genotyping via PCR.

**Figure 2: Schematic of TSC agar sandwich technique.** RPM media containing the *C. perfringens* bacteria are plated between two layers of TSC agar in order to promote an anaerobic environment.

**Figure 3: Selected PCR results.** Example images of the genotyping results of *C. perfringens* from seven different types of food, and a positive control of *C. perfringens* type B. A molecular weight ladder (first lane of each gel) was used to approximate the size of PCR results in base pairs (bp).

**Table 1: Overview of *C. perfringens* genotypes.** A chart of the combinations of toxins produced by each *C. perfringens* toxinotype.

**Table 2: Primers and expected PCR products for selected toxin genes.** Primers used in the PCR genotyping step.

**Table 3: Prevalence of different *C. perfringens* toxinotypes in 216 food samples.** An example of the results obtained when using this method to test retail food for *C. perfringens*. This table has been modified from the previously published manuscript Regan et al.<sup>16</sup>.

## DISCUSSION:

Here we describe a method to identify *C. perfringens* prevalence in retail food samples with limited subculturing and without use of an anaerobic chamber system. This method uses a combination of techniques to increase identification of *C. perfringens* from food samples. By using a modified version of RPM media, we allow for the selective growth of *C. perfringens*. By sandwiching the inoculated RPM in between layers of TSC agar, we are able to identify and isolate anaerobic, sulfite-reducing bacteria characteristic of *C. perfringens*. To confirm the presence of *C. perfringens*, sulfite-reducing colonies are sub-cultured into fresh RPM. The modified version or RPM allows us to easily extract DNA from cultures, enabling PCR confirmation of specific toxin genes. Confirmation of *C. perfringens* contaminated food samples can be achieved within three days.

In early experiments, food samples were simply inoculated into RPM and DNA extracted from ON cultures. This method resulted in detection of *C. perfringens* in a limited number of samples (data not shown). Although RPM is selective for *C. perfringens* growth, it is not exclusive for *C. perfringens* growth. Other, gram-positive, D-cycloserine resistant bacteria can still grow in RPM. We hypothesized that contamination by other bacterial species may have decreased our detection of *C. perfringens* strains by decreasing the sensitivity of our PCR analysis in our first ON RPM culture. A critical step in increasing the detection of *C. perfringens* was the inclusion of the TSC agar “sandwich” technique. This allowed us to differentiate and select for anaerobic, sulfite-reducing colonies, characteristic of *C. perfringens*. A key step in this process is ensuring that the top layer of molten TSC agar is at 40 °C. Although some *C. perfringens* strains can grow at increased temperatures (46–48 °C)<sup>15,16</sup>, addition of molten agar at increased temperatures

greatly reduces the amount of cultures recovered, mostly likely due to cell death.

There are several potential limitations to this method. As mentioned previously, neither the RPM nor TSC agar selects or differentiates for *C. perfringens* exclusively, allowing for growth of other bacterial species present in food samples. This may reduce the sensitivity of the assay to select for *C. perfringens* only. However, this is a common limitation in almost all culturing techniques. Genotyping confirmation of purified isolates is the best method for definitively identifying *C. perfringens* and other bacterial species. Another limitation of this study is that we do not test the purified isolates. We purposely did this to limit the amount of subculturing, as repeated subculturing is feared to result in plasmid loss. Because we do not isolate to purity, it is possible that multiple *C. perfringens* toxinotypes may be present in the same sample or subculture. If researchers wish to obtain purified isolates, standard purification methods can be used on the last RPM culture described in this method; this typically requires the use of anaerobic chambers. Although originally used to isolate *C. perfringens* from food, this method can be used to identify and isolate *C. perfringens* from a multitude of sources. Specifically, one such application of this method is to test fecal samples from humans (or animals) that are suspected to be infected with *C. perfringens* and toxinotype the bacteria to better understand the source of infection.

#### ACKNOWLEDGMENTS:

This research did not receive any specific funding from the public, commercial, or not-for profit sectors.

#### DISCLOSURES:

No disclosures.

#### REFERENCES:

- 1 Petit, L., Gibert, M., Popoff, M. R. Clostridium perfringens: toxinotype and genotype. *Trends in Microbiology*. **7**, 104-110 (1999).
- 2 Rood, J. I. et al. Expansion of the Clostridium perfringens toxin-based typing scheme. *Anaerobe*, doi:10.1016/j.anaerobe.2018.04.011 (2018).
- 3 Murrell, T. G., O'Donoghue, P. J., Ellis, T. A review of the sheep-multiple sclerosis connection. *Medical Hypotheses*. **19**, 27-39 (1986).
- 4 Rumah, K. R., Linden, J., Fischetti, V. A., Vartanian, T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. *PLoS One* **8**, e76359, doi:10.1371/journal.pone.0076359 (2013).
- 5 Wagley, S. et al. Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. *Multiple Sclerosis*. 1352458518767327, doi:10.1177/1352458518767327 (2018).
- 6 Linden, J. R. et al. Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination. *MBio*. **6**, e02513, doi:10.1128/mBio.02513-14 (2015).
- 7 Popoff, M. R. Epsilon toxin: a fascinating pore-forming toxin. *FEBS Journal*. **278**, 4602-

4615, doi:10.1111/j.1742-4658.2011.08145.x (2011).

8 Lee, C. A., Labbe, R. Distribution of Enterotoxin- and Epsilon-Positive *Clostridium perfringens* Spores in U.S. Retail Spices. *Journal of Food Protection*. **81**, 394-399, doi:10.4315/0362-028X.JFP-17-352 (2018).

9 Wen, Q., McClane, B. A. Detection of enterotoxigenic *Clostridium perfringens* type A isolates in American retail foods. *Applied and Environmental Microbiology*. **70**, 2685-2691 (2004).

10 Cooper, K. K., Bueschel, D. M., Songer, J. G. Presence of *Clostridium perfringens* in retail chicken livers. *Anaerobe* **21**, 67-68, doi:10.1016/j.anaerobe.2013.03.013 (2013).

11 Strong, D. H., Canada, J. C., Griffiths, B. B. Incidence of *Clostridium perfringens* in American foods. *Applied and Environmental Microbiology*. **11**, 42-44 (1963).

12 Buogo, C., Capaul, S., Hani, H., Frey, J., Nicolet, J. Diagnosis of *Clostridium perfringens* type C enteritis in pigs using a DNA amplification technique (PCR). *Journal of Veterinary Medicine, Series B*. **42**, 51-58 (1995).


13 Yamagishi, T., Sugitani, K., Tanishima, K., Nakamura, S. Polymerase chain reaction test for differentiation of five toxin types of *Clostridium perfringens*. *Microbiology and Immunology*. **41**, 295-299 (1997).

14 Johansson, A., Engstrom, B. E., Frey, J., Johansson, K. E., Baverud, V. Survival of *clostridium perfringens* during simulated transport and stability of some plasmid-borne toxin genes under aerobic conditions. *Acta Veterinaria Scandinavica*. **46**, 241-247 (2005).

15 Erickson, J. E., Deibel, R. H. New medium for rapid screening and enumeration of *Clostridium perfringens* in foods. *Applied and Environmental Microbiology*. **36**, 567-571 (1978).

16 Regan, S. B. et al. Identification of epsilon toxin-producing *Clostridium perfringens* strains in American retail food. *Anaerobe*. **54**, 124-127, doi:10.1016/j.anaerobe.2018.08.008 (2018).

Figure 1







Figure 3



Toxinotype		Alpha	Beta	Epsilon	Iota	CPE	NetB
	A	+	-	-	-	-	-
	B	+	+	+	-	-	-
	C	+	+	-	-	+	-
	D	+	-	+	-	+	-
Established	E	+	-	-	+	+	-
Proposed	F	+	-	-	-	+	-
	G	+	-	-	-	-	+

+ present  
- not present  
+/- may or may not be present

Target	Primer Pairs
alpha	F: GCT AAT GTT ACT GCC GTT GAR: CCT CTG ATA CAT CGT GTA AG
beta	F: GCG AAT ATG CTG AAT CAT CTAR: GCA GGA ACA TTA GTA TAT CTT C
epsilon	F: GCG GTG ATA TCC ATC TAT TCR: CCA CTT ACT TGT CCT ACT AAC
16s RNA	F: AGA GTT TGA TCC TGG CTC AR: GGT TAC CTT GTT ACG ACT T

Expected PCR Product (bp)
325
196
655
~1300

Food Type			Type A		Type B		Type C	
			alpha toxin positive		beta, and epsilon toxin		alpha and beta toxin positive	
			n	%	n	%	n	%
Meat	beef	38	8	21%	1	3%	0	0%
	lamb	10	0	0%	0	0%	0	0%
	pork	15	2	13%	0	0%	0	0%
	mixed	1	1	100%	0	0%	0	0%
	<b>subtotal</b>	<b>64</b>	<b>11</b>	<b>17%</b>	<b>1</b>	<b>2%</b>	<b>0</b>	<b>0%</b>
Poultry	chicken	19	5	26%	0	0%	0	0%
	turkey	7	0	0%	0	0%	0	0%
	<b>subtotal</b>	<b>26</b>	<b>5</b>	<b>19%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
Seafood	cod	4	0	0%	0	0%	0	0%
	mixed	1	0	0%	0	0%	0	0%
	salmon	11	2	18%	0	0%	0	0%
	shelfish	32	1	3%	0	0%	0	0%
	snapper	4	3	75%	0	0%	0	0%
	flounder	12	4	33%	0	0%	0	0%
	squid	4	1	25%	0	0%	0	0%
	tilapia	21	2	10%	0	0%	0	0%
	tuna	3	0	0%	0	0%	0	0%
	other	8	1	13%	0	0%	0	0%
	<b>subtotal</b>	<b>100</b>	<b>14</b>	<b>14%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
Dairy	cow	3	0	0%	0	0%	0	0%
	goat	4	0	0%	0	0%	0	0%
	milk	3	0	0%	0	0%	0	0%
	<b>subtotal</b>	<b>10</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
Produce	vegetable	12	1	8%	0	0%	0	0%
	fruit	1	0	0%	0	0%	0	0%
	herb	3	0	0%	0	0%	0	0%
	<b>subtotal</b>	<b>16</b>	<b>1</b>	<b>6%</b>	<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
Total		216	31	14%	1	0.50%	0	0%

Type D a and epsilon toxin pos		<i>C. perf</i> +	
n	%	n	%
0	0%	9	24%
0	0%	0	0%
0	0%	2	13%
0	0%	1	100%
<b>0</b>	<b>0%</b>	<b>12</b>	<b>19%</b>
0	0%	5	26%
0	0%	0	0%
<b>0</b>	<b>0%</b>	<b>5</b>	<b>19%</b>
0	0%	0	0%
0	0%	0	0%
0	0%	2	18%
0	0%	1	3%
0	0%	3	75%
0	0%	4	33%
0	0%	1	25%
2	10%	4	19%
0	0%	0	0%
0	0%	1	13%
<b>2</b>	<b>2%</b>	<b>16</b>	<b>16%</b>
0	0%	0	0%
0	0%	0	0%
0	0%	0	0%
<b>0</b>	<b>0%</b>	<b>0</b>	<b>0%</b>
0	0%	1	8%
0	0%	0	0%
0	0%	0	0%
<b>0</b>	<b>0%</b>	<b>1</b>	<b>6%</b>
2	0.90%	34	16%

Name of Material/Equipment	Company	Catalog Number	Comment:
D-Cycloserine	Sigma-Aldrich	C6880	Select one
Dextrose	Sigma Life Science	D9434-250G	
Disposable Transfer Pipets	any brand		
DNeasy Blood & Tissue Kits	Qiagen	69504	Note: num
Dry Incubator	any brand		
Fluid thioglycolate medium	Remel	R453452	
Gelatin from porcine skin	Sigma Life Science	G1890-500G	
Individual Primers	Invitrogen		
Iron (II) sulfate heptahydrate	Sigma Life Science	F8633-250 G	Needed fo
Lysozyme from chicken egg white	Sigma-Aldrich	L6876	
microcentrifuge tube	any brand		
parafilm or plastic wrap	any brand		
Peptone from casein and other animal proteins	Sigma-Aldrich	70173-100G	
Perfringens Agar Base (TSC + SFP)	Oxoid	CM0587	Make TSC
Potassium phosphate dibasic	Sigma-Aldrich	P2222-100G	
Sodium chloride	Sigma-Aldrich	S-7653	
Sterile Cell Scraper	any brand		
Sterile cell Spreader	any brand		
Sterile petri dishes	any brand		
Supplies and equipment for gel electrophoresis	any brand		
table top centrifuge	any brand		
Taq PCR Master Mix Kit	Qiagen	201443	
Thermocycler for PCR reaction	any brand		
water bath	any brand		
Yeast extract	Sigma-Aldrich	70161-100G	

## s/Description

with slim tip like Thermo Scientific Disposable Transfer Pipets 137116M/EMD

erous DNA and plasmid extractions kits were evaluated, this kit gave the most desirable results

or DNA extraction, not provided in kit

agar according to instructions



## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Enrichment and Detection of Clostridium perfringens Toxinotypes in Retail Food Samples
Author(s):	Zuha Anwar, Samantha Regan, Jennifer Linden

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access ☒ Open Access

Item 2: Please select one of the following items:

- ☒ The Author is **NOT** a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Jennifer Linden	
Department:	Brain and Mind Insitutue	
Institution:	Weill Cornell Medical College	
Title:	Instructor of Neuroscience	
Signature:		Date: 6/3/19

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

5/26/2019  
Rebuttal Letter

To Whom It May Concern:

We thank the reviewers and the editorial staff for their careful and insightful review of our manuscript entitled “An easy method for detection of *Clostridium perfringens* strains in retail food samples.”

We are excited to submit our revised manuscript for consideration. We have copied and pasted both the editorial and review comments below, and highlighted our responses in red.

Sincerely,  
Jennifer Linden, PhD

**Editorial Comments:**

- Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammatical errors. **We have carefully proofread the manuscript and edited the errors to the best of our ability.**
- Please avoid use of the pronouns “you” and “your” throughout the manuscript. **This has been completed.**
- **Protocol Detail:** Please note that your protocol will be used to generate the script for the video, and must contain everything that you would like shown in the video. **Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc) to your protocol steps.** There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Examples:
  - 1) 2.1: Are the % concentration w/v? Please provide unambiguous units e.g., g/mL instead. **This has been corrected.**
  - 2) 5.2: **How are the suspicious colonies identified? This has been explained in the text.**
  - 3) 7.1: Unclear how you performed the determination step. Please mention PCR reaction condition, primers used, etc. **This has been corrected.**
- **Protocol Numbering:** There must be a one-line space between each protocol step. **This has been corrected.**
- **Protocol Highlight:** Please highlight ~2.5 pages or less of text (which includes headings and spaces) in yellow, to identify which steps should be visualized to tell the most cohesive story of your protocol steps.
  - 1) The highlighting must include all relevant details that are required to perform the step. For example, if step 2.5 is highlighted for filming and the details of how to

perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be included in the highlighting.

2) The highlighted steps should form a cohesive narrative, that is, there must be a logical flow from one highlighted step to the next.

3) Please highlight complete sentences (not parts of sentences). Include sub-headings and spaces when calculating the final highlighted length.

4) Notes cannot be filmed and should be excluded from highlighting.

**This has been completed.**

- **Discussion:** JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please ensure that the discussion covers the following in detail and in paragraph form (3-6 paragraphs): 1) modifications and troubleshooting, 2) limitations of the technique, 3) significance with respect to existing methods, 4) future applications and 5) critical steps within the protocol.

**This has already been addressed.**

- **Figure/Table Legends:** Please expand the legends to adequately describe the figures/tables. Each figure or table must have an accompanying legend including a short title, followed by a short description of each panel and/or a general description. **This has been completed.**

- **References:** Please spell out journal names.

- **Commercial Language:** JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Examples of commercial sounding language in your manuscript are Qiagen DNease, Qiagen Taq, etc.

1) Please use MS Word's find function (Ctrl+F), to locate and replace all commercial sounding language in your manuscript with generic names that are not company-specific. All commercial products should be sufficiently referenced in the table of materials/reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names.

**This has been completed.**

- If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]." **The letter has been included and the figure level corrected.**

---

**Comments from Peer-Reviewers:**

*Please note that the reviewers raised some significant concerns regarding your method and your manuscript. Please revise the manuscript to thoroughly address these concerns. Additionally, please describe the changes that have been made or provide explanations if the comment is not addressed in a rebuttal letter. We may send the revised manuscript and the rebuttal letter back to peer review.*

**Reviewer #1:****Manuscript Summary:**

The ms describes a method for enrichment of *C. perfringens* from food sources without using an anaerobic jar. The enrichment was sufficient enough to allow multiplex PCR for gene toxotyping.

**Major Concerns:**

The methodology was not sufficiently shorter in time and costs to justify an enrichment versus a strain isolation procedure, which would provide much more information. The authors indicated this could be done after the enrichment procedure, but that defeats the purpose of having an anaerobic container-free method.

The goal of this method was to be able to detect *C. perfringens* toxinotypes in food samples by first enriching for these bacteria without using anaerobic chambers. Although obtaining purified *C. perfringens* colonies is always desirable, in our experience, is typically requires use of anaerobic chambers, and therefore was beyond the scope of this study. In addition, strain isolation and purification requires multiple subculturing steps, which can result in loss of plasmids. This is of concern when trying to toxinotype *C. perfringens*, as the majority of the major toxin genes are plasmid bound. This is addressed in the introduction. Finally, in an attempt to better reflect the goal of our method, we have changed the title of the manuscript to "An easy method for enrichment and detection of *Clostridium perfringens* toxinotypes in retail food samples".

**Minor Concerns:**

Multiple typos in the text.

We have carefully proofread the manuscript and edited the errors to the best of our ability.

**Reviewer #2:****Manuscript Summary:**

Interesting methods- methodology to culture anaerobic bacteria without a chamber.

**Major Concerns:**

Line 53: Capitalize Gram. Thank you, this has been corrected.

Line 254: If the media is not selective to the pathogen then this could be an issue. Is

there a way to use selective media for *C. perfringens*? If not, this limitation needs to be addressed early on in the manuscript.

We agree that this is an unfortunate issue. However, there is not a growth medium exclusively selective for *C. perfringens*. In preliminary experiments, we found that more samples tested positive for *C. perfringens* when cultured first in RPM versus other media typically used to grow this species. Therefore, we decided to continue to use RPM as our “semi-selective” medium. The limitation of RPM as a “semi-selective” medium is addressed in the discussion section of this manuscript per direction of JoVE’s editorial staff.

Line 273: correct researches to researchers. Thank you, this has been corrected.

## ELSEVIER LICENSE TERMS AND CONDITIONS

May 23, 2019

This Agreement between Dr. Jennifer Linden ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4594890118116
License date	May 23, 2019
Licensed Content Publisher	Elsevier
Licensed Content Publication	Anaerobe
Licensed Content Title	Identification of epsilon toxin-producing Clostridium perfringens strains in American retail food
Licensed Content Author	Samantha B. Regan,Zuha Anwar,Patricia Miraflor,Libra B. Williams,Sarah Shetty,Juan Sepulveda,Jake Moreh,Sam Bogdanov,Sylvia Haigh,Abigail Lustig,Steffi Gaehde,Anthony Vartanian,Noah Rubin,Jennifer R. Linden
Licensed Content Date	Dec 1, 2018
Licensed Content Volume	54
Licensed Content Issue	n/a
Licensed Content Pages	4
Start Page	124
End Page	127
Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
Format	electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	Table 1
Title of the article	An easy method for detection of Clostridium perfringens strains in retail food samples
Publication new article is in	JoVE
Publisher of the new article	Other
Author of new article	Zuha Anwar, Samantha B Regan, Jennifer Linden
Expected publication date	Sep 2019
Estimated size of new article (number of pages)	8
Requestor Location	Dr. Jennifer Linden

75 Colonial Springs Rd  
Gate 2

WYANDANCH, NY 11798  
United States  
Attn: Dr. Jennifer Linden

Publisher Tax ID 98-0397604

Total 0.00 USD

[Terms and Conditions](#)

## INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

## GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement

and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

### LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

**Preprints:**

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
  - directly by providing copies to their students or to research collaborators for their personal use
  - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use

for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above:

Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

#### **Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

#### **Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the

license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee. Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

## 20. Other Conditions:

v1.9

Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

---

---